Betrixaban activates cGAS-STING to promote antitumor immunity without pathological inflammation.
An already-approved blood thinner may boost cancer-fighting immune cells and work better with checkpoint inhibitor drugs.
This EMBO Molecular Medicine study demonstrates that betrixaban, an FDA-approved anticoagulant, functions as a dual immunomodulator by activating cGAS-STING via a noncanonical pathway, boosting antitumor CD8+ T cell responses and synergizing with checkpoint inhibitors without triggering pathological inflammation. The finding that an approved drug can address the antitumor/anti-inflammatory balance problem in cancer immunotherapy is a novel mechanistic discovery with translational potential.
What the study was
- Study design
- Preclinical mechanistic study
- Population
- Mouse tumor models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- EMBO Molecular Medicine
Why it surfaced
NOVEL_TREATMENT flag: FDA-approved drug repurposed as dual immunomodulator via noncanonical cGAS-STING activation. Solves the longstanding problem of ICI-associated immune toxicity by simultaneously enhancing antitumor immunity and suppressing hyperinflammation. Score capped at 5 per non-human study rule; pipeline_priority elevated to HIGH per NOVEL_TREATMENT flag.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.